The use of Orgovyx requires special attention to cardiovascular risks, endocrine effects, and medication safety for special populations. Regular monitoring of relevant indicators and attention to drug interactions are necessary. The following categories explain specific precautions. If serious adverse reactions occur, immediate medical treatment is required.

1. Cardiovascular system monitoring

Risk of QT interval prolongation: Before medication, it is necessary to complete an electrocardiogram examination to avoid the combination of fluoroquinolones, tricyclic antidepressants, and other QT prolonging drugs. Elderly patients and those with electrolyte imbalances are at higher risk.

Hypertension management: Patients with baseline blood pressure ≥ 140/90mmHg need to control before medication. During the treatment period, blood pressure is monitored weekly, and if there is a persistent increase, the blood pressure reduction plan needs to be adjusted.

2. Effects on the endocrine system

Fluctuations in testosterone levels: There may be a brief increase (7-14 days) during the initial stages of medication, followed by sustained inhibition. Testosterone needs to be tested in weeks 4 and 12 to maintain a target value of<50ng/dL.

Blood glucose monitoring: it may cause insulin resistance. diabetes patients need to strengthen blood glucose monitoring and be alert to ketoacidosis symptoms.

3. Medication for special populations

Liver dysfunction: Moderate injury (Child Pugh B) requires a 50% reduction, while severe injury (Child Pugh C) is contraindicated. Monitor ALT/AST monthly.

Renal insufficiency: CrCl30-89mL/min does not require adjustment, and is contraindicated for patients with<30mL/min or dialysis. Monitor electrolyte balance.

4. Drug interactions

CYP3A4 inhibitors, such as clarithromycin and itraconazole, can increase blood drug concentrations and should be avoided in combination or adjusted in dosage.

P-gp substrate: When used in combination with digoxin, the concentration of the latter needs to be monitored to prevent poisoning.

5. Other important matters

Contraceptive requirements: Women of childbearing age should use non hormonal contraceptive measures during treatment and within 2 weeks after discontinuing medication, as medication may reduce the effectiveness of hormonal contraception.

Indications for discontinuation: permanent discontinuation is required if QTc>500ms, allergic reactions, or grade 3 or above liver toxicity occur.